Cosmos Health Inc. — Form 8-K
Filed October 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Cosmos Health reported preliminary nine-month 2026 revenue of $54.3M (up 19% or $8.7M from $45.6M in 9M 2025), with Q3 2026 at $17.4M (up 2% from $17.1M in Q3 2025, up 40% YoY). The company reaffirmed full-year 2026 revenue outlook exceeding $90M (38% growth vs. 2025's $65.3M). Growth spans all segments: Cana Laboratories contract manufacturing reached 32.7M unit pipeline; CosmoFarm pharmaceutical distribution serves 1,500+ pharmacies; proprietary brands (Sky Premium Life, C-Sept, C-Scrub) expanded globally with accelerating U.S. momentum.
Why this rating
Nine-month revenue ($54.3M) is 5.7x company market cap ($9.5M)—revenue alone dwarfs valuation. 19% growth, record quarters, and reaffirmed $90M+ full-year outlook signal strong execution and momentum. However, figures are preliminary/unaudited, and $9.5M market cap leaves limited room for valuation re-rating absent near-term earnings proof. Meaningful progress but not yet transformational.
Price action (we called it positive)
before filing · preread $0.34 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.